All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On January 4, 2023, briquilimab, a monoclonal antibody targeting the CD117 receptor, was granted orphan drug designation by the European Commission, as a conditioning treatment prior to hematopoietic stem cell transplantation (HSCT).1 Briquilimab received orphan drug designation from the U.S Food and Drug Administration (FDA) in June 2022.1
As previously reported by the AML Hub, briquilimab is currently being investigated as a conditioning treatment prior to HSCT in patients with acute myeloid leukemia and myelodysplastic syndromes (MDS).1 Briquilimab was found to have a tolerable safety profile, with full donor chimerism in all 24 patients with acute myeloid leukemia or MDS. There were no reports of treatment-related significant adverse events, classical acute Grade II–IV graft-versus-host disease, or transplant mortality within 100 days. Briquilimab is also being assessed as a primary therapy for patients with low-risk MDS and as a conditioning therapy prior to HSCT for patients with severe combined immunodeficiency.1
JSP191 conditioning for patients with AML or MDS: Preliminary results from a phase I clinical trial
During the 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, positive preliminary data from a phase I trial (NCT04429191),...
EHA 2019 | Recent advances in the field of allo-HSCT
Uwe Platzbecker from the University Hospital Leipzig, DE, discusses recent advances in allogeneic stem cell transplantation (allo-SCT).
Subscribe to get the best content related to AML delivered to your inbox